Literature DB >> 36159098

Prevalence of human leishmaniasis in Sudan: A systematic review and meta-analysis.

Musa Ahmed1,2, Abdullah Abdulslam Abdullah1,3, Idris Bello1,4, Suad Hamad5, Aboelgassim Bashir6.   

Abstract

BACKGROUND: There are three main forms of leishmaniasis in humans: cutaneous leishmaniasis (CL), visceral leishmaniasis (VL), and mucocutaneous leishmaniasis. The prevalence of human leishmaniasis varies widely in different countries and different regions of the same country. To date, there is no overall estimation of the prevalence of human leishmaniasis in Sudan. AIM: To determine the pooled prevalence of human leishmaniasis and the disease risk factors among Sudanese citizens.
METHODS: From all articles written in English or Arabic languages conducted before the 4th of August 2021 from [Scopus, Web of Science, PubMed, and MEDLINE, African Journals Online (AJOL), ResearchGate, direct Google search, Google Scholar, and universities websites], just 20 articles with a total of 230960 participants were eligible for this study. Data synthesis and analysis were done using STATA software, version 16. EndNote citation manager version X9.3.3 and Reference Citation Analysis (RCA) were used to remove the duplicated studies and manage the citation respectively.
RESULTS: The overall pooled prevalence of human leishmaniasis in Sudan was 21% (with confidence interval 12%-30%). CL was the most common type of leishmaniasis in Sudan, with a pooled prevalence of 26% followed by VL (18%). Nevertheless, the pooled prevalence of human leishmaniasis in Sudan was higher in males compared with females (60% vs 40%). The current results revealed that the people in the age group between 15 and 44 were the most affected group (60%), and central Sudan has the highest pooled prevalence of human leishmaniasis (27%) compared with other regions of Sudan. Finally, the prevalence of human leishmaniasis seems to decrease with time.
CONCLUSION: This study showed that human leishmaniasis infection is still endemic in many regions in Sudan and highly prevalent in central and eastern Sudan, and CL is the most prevalent in the country. Males and adults were more susceptible to infection compared with females and children. However, the human leishmaniasis prevalence decreased relatively over time. ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Entities:  

Keywords:  Cutaneous leishmaniasis; Human leishmaniasis; Meta-analysis; Prevalence; Sudan; Visceral leishmaniasis

Year:  2022        PMID: 36159098      PMCID: PMC9350725          DOI: 10.5662/wjm.v12.i4.305

Source DB:  PubMed          Journal:  World J Methodol        ISSN: 2222-0682


Core Tip: A comprehensive systematic review and meta-analysis study was conducted to find the pooled prevalence of leishmaniasis and its associated factors among Sudanese citizens. After applying all required quality check-ups for the individual studies, 20 studies were included in this study. The pooled prevalence of human leishmaniasis in Sudan was 21%, and cutaneous leishmaniasis was the commonest form of leishmaniasis in Sudan. Finally, the results of this study showed that human leishmaniasis infection is still endemic in many regions in Sudan.

INTRODUCTION

Neglected tropical zoonotic diseases (NTZDs) are endemic diseases in many developing countries of Africa, Asia, and Latin America[1]. The WHO's annual report for 2021, revealed that leishmaniasis is set among the top ten NTZDs worldwide[2]. In addition to the zoonotic nature of the disease, leishmaniasis is transmitted to humans by the infected female sandflies with Leishmania parasite, when it feeds on the human's blood[3]. There are three main forms of the disease in humans: cutaneous leishmaniasis (CL), which mainly features skin lesions, visceral leishmaniasis (VL), or Kala-azar, which can affect the spleen, liver, and bone marrow leading to some serious symptoms, and mucocutaneous leishmaniasis (ML)[3]. Of the three leishmaniasis forms, VL is the most lethal with a fatality rate of 95% if it is left untreated, while CL is the most common form[2]. In general, the high incidence and prevalence of human leishmaniasis have been highly associated with the prevalence of conditions that leads to a weak immune response, such as AIDS or tuberculosis. Studies also found a strong association between leishmaniasis prevalence and poor household status, poverty, population displacement, and recent climate change[4-7]. Evidence showed that the annual incidence of human leishmaniasis was 700000 to 1 million new cases. Although the disease was reported in 89 countries all around the world, East Africa, Southeast Asia, and South America countries, have the highest incidence rates[8]. Nevertheless, almost all reported outbreaks of human leishmaniasis were from East African countries, namely Sudan, South Sudan, and Ethiopia[9-13]. Sudan has a long history of leishmaniasis which was firstly discovered by Neave in the early 1900s[14]. Moreover, in the late twentieth century, several leishmaniasis (CL & VL) outbreaks were reported in the eastern and central parts of the country[15]. The geographical distribution study of human leishmaniasis in Sudan found a high relationship between disease occurrence and vector distribution[16,17]. Reports from Sudan found that the VL is endemic in the country, especially in the savannah area in the eastern and central parts of the country, which lies between four states (White Nile State in the west, Gadarif state in the east, Blue Nile State in the south, and Kassala state in the northeast)[18]. Moreover, VL was reported outside the savannah area in some scattered foci in the western parts of the country in Darfur states and Kordofan states[19]. Furthermore, national-wide epidemiological studies, report the endemic presence of the CL, especially in the northern, central, and western parts of the country[15]. For all the above reasons, it can be said that human leishmaniasis (both CL & VL) is endemic in Sudan, and the disease represents a serious health problem that affects the whole healthcare system[20]. Despite the importance of the disease in Sudan and the many published studies across the country that described the epidemiology of human leishmaniasis, no study estimated the overall prevalence of the disease at the national level exists to date. The lack of evidence about the disease in the country may prevent the health care policymakers and stakeholders from developing and adopting a suitable prevention program. Thus, the current study aimed to investigate the pooled prevalence of human leishmaniasis (both CL and VL) in Sudan.

MATERIALS AND METHODS

Eligibility criteria

The following were the eligibility criteria of this study: (1) All human observational studies; (2) Done on the Sudanese population; (3) Published in Arabic or English; (4) Reported the prevalence of human leishmaniasis (CL and VL); and (5) The positive cases of leishmaniasis were detected using the standards' diagnostics methods (serological and molecular tests). Moreover, studies were not eligible for this study (1) If they were reviews, letters, editorials, animal studies; and (2) If the full text was not available and has been requested from the author(s) through email but no feedback was received after 2 wk.

Information sources

This meta-analysis study was conducted according to the guideline of Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)[21]. The relevant information was retrieved from the electronic databases sources, namely Scopus, Web of Science, PubMed, MEDLINE, African Journals Online (AJOL), ResearchGate, direct Google search, Google Scholar, and universities websites. All indicated databases were searched from their inception to the 4th of August 2021, for human studies published in English and/or Arabic.

Search strategy

To achieve the current study objectives, a research strategy was developed using the Boolean search terms (AND, OR, NOT). The final search strategy included the use of Title/Abstract related to ((human leishmaniasis) AND ((prevalence) OR (epidemiology) OR (frequency)) OR (Risk factors)) AND Sudan) taken from the study questions. In addition, a manual search was done by the investigators for the grey literature and unpublished thesis/papers.

Selection process

Initially, primary screening was done based on the inclusion and exclusion criteria. Thereafter, all retrieved studies were exported to the EndNote citation manager version X9.3.3, to remove the duplicated studies. After that, the remaining articles were screened and evaluated by two investigators (Ahmed M and Abdulslam Abdullah A) independently. The investigators carefully have read the title, abstract, and full text of each article to eliminate the unrelated studies to prior defined objectives. Furthermore, the remaining articles were considered for further quality checkups against the checklist of Joanna Briggs Institute quality assessment tools[22]. Any discrepancy in the study findings was resolved by discussion between the two authors (Ahmed M and Abdulslam Abdullah A) or by consulting Hamad S. Figure 1 shows the selection process using the PRISMA statement flow diagram. Finally, Reference Citation Analysis (RCA) were used to manage the citation.
Figure 1

Flow diagram of the studies included in this meta-analysis.

Flow diagram of the studies included in this meta-analysis.

Data collection process

Following the selection process, the relevant data were extracted using a Microsoft word 2016 data extraction template. Two investigators (Ahmed M and Abdulslam Abdullah A) contacted the corresponding author of any study that failed to report the information required for the eligibility criteria indicated above (via email) to get the original data; however, if the missing data were not obtained after 2 wk, a sensitivity analysis was carried out to remove the studies with the missing information. The extraction template contains (author/s name and publication year, study period, study design, study setting, geographical location (based on state names), type of leishmaniasis (VL & CL), sample size, diagnostic method, and the prevalence of leishmaniasis in (overall and male and female) (Table 1). The accuracy of the data extraction process was verified by comparing the extraction results of 2 authors (Ahmed M and Abdulslam Abdullah A), who extracted the data independently, in a randomly- chosen set of papers (30% of the total).
Table 1

Main characteristics of studies included in the meta-analysis

Ref.
Sample size
Method
Type of leishmaniasis
Geographical location
Study design
Study setting
Prevalence n (%)
Overall, n %
Male
Female
Hashim[24], 1997126PCR & LSTVL/CLCentral SudanCSHB43 (34.1)NRNR
El Dawi[25], 199444 DATVLCentral SudanPSHB19 (43.2)NRNR
Ibrahim[26], 2012734LSTCLCentral SudanCSCB73 (9.9)NRNR
Sharief et al[27], 2019 1781DAT & LSTVLWestern SudanESCB238 (13)NRNR
Osman[28], 2011332PCRCLWestern SudanCSCB32 (9.6)NRNR
Noraldaim[29], 2012110DAT & ELISAVLCentral SudanPSCB46 (41.8)NRNR
Mohamed et al[30], 201995DATVLEastern SudanCSCB5 (5.3)NRNR
Dereure et al[31], 200379CultureVLEastern SudanNRCB23 (29.1)NRNR
EL-Safi et al[18], 2002947DAT & LSTVLEastern SudanCSCB132 (13.9)NRNR
El-Safi and Peters[32], 19919657DATCLCentral SudanRSHB736 (7.6)449 (61)287 (39)
Atia[23], 2012373DATVLEastern SudanCSCB64 (17.2)29 (45.3)35 (54.7)
Abdallah[34], 2015352DAT & ELISAVLEastern SudanPSHB71 (20.2)43 (60.6)28 (39.4)
Ebrahim[19], 201648972MixedVLWestern SudanRSHB815 (1.7)(62)(38)
Awadalla[35], 2007399DATVLEastern SudanCSCB35 (8.8)23 (65.7)12 (34.3)
Muawyia et al[36], 202140DATCLCentral SudanNRHB13 (32.5)10 (76.9)3 (23.1)
Osman et al[37], 2021410LSTCLNorthern SudanCSCB290 (70.7)91 (31.4)199 (68.6)
Abdullah et al[38], 2021162443MixedVL/CLWestern SudanRSHB7131 (4.4)4657 (65.3)2474 (34.7)
Ahmed[39], 201150MixedVLCentral SudanCSHBNR38 (76)12 (24)
Ahmed[40], 2017215MixedVLEastern SudanR-CCHBNR140 (65.1)75 (34.9)
Collis et al[41], 20193801LSTCLNationwideRSHBNR2178 (57.3)1599 (42.1)

CB: Community-based study; CL: Cutaneous leishmaniasis; CS: Cross sectional study; DAT: Direct agglutination test; DS: Descriptive study; ELISA: Enzyme-linked immunosorbent assay; ES: Epidemiological surveys; HB: Hospital-based study; LST: Leishmania skin test; NR; Not reported; PCR: Polymerase chain reaction; PS: Prospective study; R-CC: Retrospective case-control study; RS: Retrospective study; VL: Visceral leishmaniasis.

Main characteristics of studies included in the meta-analysis CB: Community-based study; CL: Cutaneous leishmaniasis; CS: Cross sectional study; DAT: Direct agglutination test; DS: Descriptive study; ELISA: Enzyme-linked immunosorbent assay; ES: Epidemiological surveys; HB: Hospital-based study; LST: Leishmania skin test; NR; Not reported; PCR: Polymerase chain reaction; PS: Prospective study; R-CC: Retrospective case-control study; RS: Retrospective study; VL: Visceral leishmaniasis.

Data items and effect measures

The prevalence of human leishmaniasis in Sudan was the main outcome of the current study. Moreover, the prevalence was measured from the individual studies by the direct report. To quantify the outcome, studies that reported the prevalence of VL and/or CL in their statistics were considered. Finally, the result was interpreted by the proportions of the population who tested positive for leishmaniasis compared with the total population studied.

Study risk of bias assessment

The risk of bias for this study was checked through several steps: firstly, by appraising the eligibility criteria for all retrieved articles by checking the title and abstract for each retrieved study; secondly, the full-text for each included study from step one was screened using the quality assessment criteria to identify their quality before the final selection. The quality assessment criteria used to determine if the study could be included were: (1) The presence of Leishman parasite in the patient was identified after performing the appropriate diagnostic tests; and (2) From the statistical point of view, the study sample was representative of the study population. To minimize the risk of bias two strategies were followed: (1) A comprehensive search for all electronic and non-electronic databases; and (2) A critical appraisal tool (Joanna Briggs Institute Quality Assessment Tool)[22] was used by two investigators (Ahmed M and Abdulslam Abdullah A) independently to critically appraise the included studies. The publication bias in the current review was checked primarily by Egger’s regression test, which is a test of statistical symmetry of the funnel plot. Also, visualizing the inspection of the funnel plot was used to check the publication bias.

Registration and protocol

This review was developed based on the PRISMA guideline[21]. The review protocol has been registered by the International prospective register of systematic reviews at https://www.crd.york.ac.uk/Prospero/#recordDetails (No. CRD42021270418).

Synthesis methods

The collected study data were synthesized and analyzed using the STATA software, version 16.0 (Stata Corp LLC, 77845 Texas, United States). Statistically significance was set for P values < 0.05. The heterogeneity test was conducted using the degree of inconsistency (I2), which is a percentage, and range from (0%-100%), moreover, Higgins et al[23] described the heterogeneity to be low, medium, and high, for the (I2) values of 25%, 50%, and 75% respectively. Two statistical measurements were used to calculate the result of this study: effect size with a 95% confidence interval (CI) and standard error (SE). The prevalence of leishmaniasis (proportion) was considered as the effect size of this study, and the binomial distribution was used to calculate it. The standard error was calculated using the following data: sample size (n) and the proportion of leishmaniasis positive case among the overall population (p) using the SE formula: SE = sqrt[p (1-p) / n). In the final meta-analysis model, the outcome of each individual study, as well as the pooled outcome of all included studies, were presented as forest plots [reported as effect size (prevalence) with a 95%CI]. The visual symmetry of the funnel plot and the result of Egger’s Regression were used to check the potential publication bias; however, unlike other statistical tests reported here, the Egger’s test was considered significant if the P values were less than 0.10. A meta-regression test was conducted (univariate and multivariate regression) to investigate the possible relationship between study variables (study year/s, sample size, diagnostic method, type of leishmaniasis, study region, study design, and study setting) and the prevalence of human leishmaniasis. Sensitivity analysis and subgroup analysis were performed to check the potential heterogeneity among the included studies and possible sources of bias. Finally, the findings of this study were reported according to the PRISMA guidelines[21], and the results were presented using a narrative synthesis and followed by the full meta-analysis chart.

RESULTS

Study selection

After applying the search strategies of the current study, a total of 220 articles were identified and retrieved from the major electronic databases sources. From the 220 retrieved articles, 111 of them were removed due to duplication. Meanwhile, the remaining 109 articles underwent further individual screening by title and abstract to appraise the eligibility criteria for each included study. Only 39 records were eligible for full-text quality assessment. Of the remaining 39 articles, 19 were excluded due to the article's poor quality and insufficient study data. Eventually, only 20 studies with good quality assessment scores that fulfilled the eligibility criteria were included in this review. Figure 1 showed the full process of study selection.

Study characteristics

As shown in Table 1, twenty studies with a total of 230960 participants, were included in the quantitative analysis. Of these 20 studies, 10 were community-based studies, and the remaining 10 studies were hospital-based. The overall prevalence of human leishmaniasis in Sudan was reported in 17 studies, and the association between sex and leishmaniasis was reported in 11 studies. Meanwhile, two types of human leishmaniasis were reported (CL & VL). The geographical distributions of included studies revealed that the most frequent study areas in the included studies were central and eastern Sudan (7 for each), followed by western Sudan (4), with only one study from northern Sudan, and no study from southern Sudan. From all available diagnostic tests for leishmania parasite, only five were mentioned in the included studies: (1) Direct agglutination test (DAT) - 11 times; (2) Leishmania skin test (LST) - 5 times; (3) Polymerase chain reaction (PCR) - 2 times; (4) Enzyme-linked immunosorbent assay test (ELISA) - 2 times; and (5) Culture method - 1 time.

Results of synthesis

The current comprehensive study found a wide range of human leishmaniasis prevalence in Sudan in the twenty included studies. The lowest prevalence of human leishmaniasis, 1.7 (95%CI: 1, 2.8) was reported in a study in North Darfur state[19], whereas, the highest prevalence, 70.7% (95%CI: 66, 75), was reported in a study done in Al-tragma Village, River Nile state[37]. From the included studies, the pooled prevalence of human leishmaniasis in Sudan was 21% (CI: 12%-30%), and the heterogeneity across studies was substantially high (with P < 0.00001; I2 = 98.9%); therefore, the random effect model (REML) was employed for the final analysis (Figure 2).
Figure 2

Forest plot (random-effects model) for the pooled prevalence of human leishmaniasis in Sudan.

Forest plot (random-effects model) for the pooled prevalence of human leishmaniasis in Sudan.

Meta-regression and sensitivity analysis

A meta-regression test was conducted (both univariate and multivariate regression) to investigate the possible relationship between study variables (study year/s, sample size, diagnostic method, type of leishmaniasis, study region, study design, and study setting) and the prevalence of human leishmaniasis. Nevertheless, all examined variables were not found to be statistically significant (Table 2), and from that, it can concluded that these study variables did not affect the heterogeneity. Alongside, the meta-regression, a sensitivity analysis was performed to identify the possible sources of the heterogeneity among the included studies. This study was done by sequentially excluding studies from the analysis model, but again the results did not find any significant difference in the analysis model. Thus, it can be concluded that the meta-analysis result of this study was stable. Furthermore, Egger's test for publication bias was statistically insignificant P = 0.128.
Table 2

Heterogeneity related variables for the prevalence of human leishmaniasis in the current meta-analysis (based on meta regression)

Variables
Coefficient
SE
t
P > |t|
95%CI
Study yr/s-0.01833710.0892299-0.210.841(-0.2171537, 0.1804794)
Sample size-1.46e-061.10e-06-1.330.204(3.80e-06, 8.83e-07)
Diagnostic method0.01523740.05003730.300.767(-0.0962528, 0.1267275)
Type of leishmaniasis-0.02718580.0653937-0.420.686(-0.172892, 0.1185204)
Study region-0.04724260.0775729-0.610.556(-0.2200857, 0.1256005)
Study design0.00299820.05844590.050.960(-0.1272273, 0.1332237)
Study setting-0.03811690.1762884-0.220.833(-0.4309118, 0.354678)

CI: Confidence interval.

Heterogeneity related variables for the prevalence of human leishmaniasis in the current meta-analysis (based on meta regression) CI: Confidence interval.

Subgroup analysis

Given the very high heterogeneity level presented in the analyses of human leishmaniasis, a subgroup analysis was done to find the effect of the sex, age, study year's, type of leishmaniasis, study region, study design, and study setting on the pooled prevalence of human leishmaniasis (Table 3). Using the above-mentioned factors as risk factors, the study results found that CL was the most common type of leishmaniasis in Sudan, with a pooled prevalence of 26% followed by combined infection (VL & CL) 19%, and then VL at 18%. Despite this, no data were found about ML prevalence in Sudan (Figure 3).
Table 3

Subgroup analysis findings (random-effects model)

Analysis of leishmaniasis
Number of studies/pooled sample size
Pooled prevalence % (95%CI)
T2
I 2 %
H2
P value
SexMale10/1321860 (52-67)0.0197.9649.09< 0.001
Female10/1321840 (33-48)0.0197.9649.07< 0.001
Age group< 55/83263 (1-6)0.00199.9918316.61< 0.001
5-145/832622 (12-32)0.0197.7644.50< 0.001
15-445/832660 (50-69)0.0195.5322.38< 0.001
≥ 455/832614 (9-19)0.00192.0912.63< 0.001
Types of human leishmaniasisVL10/5315218 (10-27)0.0299.28138.39< 0.001
CL5/1117326 (2-50)0.0799.79485.11< 0.001
VL/CL2/16256919 (10-48)0.0497.9849.48< 0.001
Study regionCentral Sudan6/1071127 (14-40)0.0298.8687.63< 0.001
Eastern Sudan6/224515(9-21)0.0193.8416.23< 0.001
Northern Sudan1/41071(66-75)----
Western Sudan4/2135287 (2-12)0.0099.972882.28< 0.001
Study yr/sBefore 20005/1085324 (12-37)0.0298.883.02< 0.001
Between 2001 to 20104/92224 (9-39)0.0296.8331.54< 0.001
After 20118/21511917 (1-32)0.0510024190.74< 0.001
Study settingHospital-based study8/22171320 (10-31)0.0299.9911092.03< 0.001
Community-based study9/518121 (7-35)0.0599.54218.75< 0.001

I 2 index for the degree of heterogeneity; T2 measure of heterogeneity; CI: Confidence interval; CL: Cutaneous leishmaniasis; VL: Visceral leishmaniasis.

Figure 3

Forest plot (random-effects model) for the pooled prevalence of the types of human leishmaniasis in Sudan.

Forest plot (random-effects model) for the pooled prevalence of the types of human leishmaniasis in Sudan. Subgroup analysis findings (random-effects model) I 2 index for the degree of heterogeneity; T2 measure of heterogeneity; CI: Confidence interval; CL: Cutaneous leishmaniasis; VL: Visceral leishmaniasis. Nevertheless, the pooled prevalence of human leishmaniasis in Sudan was higher in males (60%) compared with females (40%) (Figure 4). In addition, the current results revealed that the people in the age group between 15 and 44 were the most affected group (60%) (Figure 5), central Sudan has the highest pooled prevalence of human leishmaniasis (27%) compared with other regions of Sudan, and the prevalence of human leishmaniasis seem to decrease over time (Table 3).
Figure 4

Forest plot (random-effects model) for the pooled prevalence of human leishmaniasis in males and females in Sudan.

Figure 5

Forest plot (random-effects model) for the pooled prevalence of human leishmaniasis in different age groups in Sudan.

Forest plot (random-effects model) for the pooled prevalence of human leishmaniasis in males and females in Sudan. Forest plot (random-effects model) for the pooled prevalence of human leishmaniasis in different age groups in Sudan.

DISCUSSION

The United Nations Environment Programme 2020 annual report revealed that the majority of the Sudanese population live in the river Nile bank, forest zones, and savannah[42,43]. These areas are the natural areas for the presence of the carrier host (Sandfly)[17]. Also, the unique geographical location of Sudan, which is characterized by long staggered borders with some of leishmaniasis endemic areas on the southern and eastern sides of the country, together with the fact that the majority of the population are either nomad or farmers, make it very hard to control the disease in the country. Thus, human leishmaniasis poses an important challenge for the health and economic sectors in Sudan. Based on a REML, the overall pooled prevalence of human leishmaniasis in Sudan was 21% (95%CI: 12%-30%). Assefa (2018), in Ethiopia, found almost the same result 21% (95%CI: 15%-27%)[44]. However, another Ethiopian study in 2021 found a lower result 9.13% (95%CI: 5-13.27)[45]. This difference between the two Ethiopian studies may be large because of the difference in the number of included studies between them, which was 27 and 11, for Assefa[44], 2018, and Haftom et al[45], 2021, respectively. Although both Ethiopia and Sudan are endemic countries, the overall prevalence showed a clear discrepancy. The current findings showed variations in the pooled prevalence of human leishmaniasis between different geographical regions, age groups, sex, study settings, and years of publication, as well as between the different forms of human leishmaniasis. However, these findings showed no statistical difference in all subgroup analyses. Two forms of human leishmaniasis were reported in Sudan, CL & VL, and between them, CL had the highest pooled prevalence of 26%, followed by mixed infection (CL & VL) (19%), and VL (18%). These results are in agreement with WHO findings[2] and Assefa's (2018) findings[44]. In contrast, Haftom and his colleagues (2021)[45] found a higher pooled prevalence of VL compared with CL in Ethiopia. Furthermore, the pooled prevalence of VL in Sudan was significantly higher than in Iran (2%)[46,47] and lower than it is in Latin America at 38.8%[48]. However, the current results seem to have one the highest reported pooled prevalence of CL worldwide, with only Sabzevari and his colleagues (2021)[49] in Iran reporting a higher pooled prevalence (45%); all other studies reported a lower pooled prevalence of CL compared with the current findings, including 22.1% in Mali[50], and 6.03%[45], and 19%[44] in Ethiopia. The reported difference in the results between the other studies and this study may be due to differences in the climate of the study area, the study population, the absence of routine treatment or vaccinations for the definitive host, sample size, sampling procedure, and/or diagnostics method[51,52]. In Sudan usually, men work in agriculture and/or livestock sectors more than women and during the hot evenings and nights, men wear fewer clothes than women. These two main reasons may explain increased prevalence of leishmaniasis in Sudanese males compared with females (60% vs 40%), as these likely an increased risk of sand flies biting. These findings are in agreement with Haftom et al[45] (2021) in Ethiopia, Belo et al[53] (2013) in the Americas, and Kone et al[50] (2016) in Mali. However, two Iranian studies[47,49] disagreed with the current findings, with both studies reporting that the pooled prevalence of human leishmaniasis (CL & VL) was higher in females than in males. The sex-related difference in the pooled prevalence of human leishmaniasis between the current study and the Iranian studies may be due to differences in the cultural and work patterns between Sudan and Iran, Whereby, Iranian women were more involved in agricultural and livestock activities than men which would increase their risk of being bitten by sand flies[49,54]. The association between human leishmaniasis and age was reported in very few studies[26,32,35,37,38]; however, the pooled result reveals that people of workforce age had the highest pooled prevalence, followed by school-aged children and the infants. This makes sense because people who work in the agriculture and/or livestock sectors are at a higher risk of being bitten by sand flies. Similar results were found in Iran[47,49], Mali[50], and the Americas[53]. This meta-analysis study found that central Sudan has the highest reported pooled prevalence of human leishmaniasis compared with other parts of the country, and, generally, the pooled prevalence of human leishmaniasis in Sudan was decreasing over time. This result is corresponding with Al-Salem et al[6] (2016), who stated that “between 1985 and 2005, many epidemics of VL and CL were reported in Sudan, especially in central Sudan”, and resulting from that, a high overall prevalence of human leishmaniasis in the same period of time in central Sudan. The relatively high prevalence of human leishmaniasis in Sudan may be due to the negative effects of the Sudanese civil war. Consequently, the overall prevalence of human leishmaniasis and VL were significantly decreased after the leaders of the two war parties [The federal government of Sudan and the Sudan People's Liberation Army (SPLA)] signed the Comprehensive Peace Agreement on January 9, 2005 to stop the ongoing civil war[55]. Despite the seriousness of human leishmaniasis in Sudan, as presented in the current comprehensive study, no data is available about the economic impact of the disease on the livestock sector and public health sector in the country; thus, work needs to be done to cover the gap in this area. In addition, in our humble opinion, a collaborative effort and immediate action need to be taken from the policymakers and governments (federal and state government), to adopt a national wide epidemiological program to clarify the design of regional strategies and to guide the development of prevention and eradication programs in light of the one health concept during and beyond the COVID-19 pandemic. The strengths of this study were the use of comprehensive search strategies to ensure that all published and unpublished studies related to the study objectives were included, and the use of standardized quality tools to evaluate the quality of the included studies. Finally, studies with abstracts were only included in this study. The absence of data about patient places of residence, Leishman parasite species, and other potential risk factors in some included studies, are considered as limitations of the current study. To the best of our knowledge, the current study is the first systematic review and meta-analysis study regarding the epidemiology of leishmaniasis in Sudanese citizens. Unluckily, there are very few published meta-analysis studies on the overall prevalence of human leishmaniasis, particularly in developing countries to compare with.

CONCLUSION

This systematic review and meta-analysis showed that human leishmaniasis infection is still endemic in many regions in Sudan and highly prevalent in central and eastern Sudan, and cutaneous leishmaniasis is the most prevalent in Sudan. Males and adults were more susceptible to infection compared with females and children. However, the human leishmaniasis prevalence decreased relatively over time. The presence of the high heterogeneity among the included studies should be considered when interpreting this study's findings. There is a lack of published research about human leishmaniasis in northern and southern regions Sudan. Research need to be updated and more research needs to be conducted in many regions in Sudan to provide adequate information.

ARTICLE HIGHLIGHTS

Research background

The prevalence of human leishmaniasis varies widely in different countries and in different regions of the same country. To date, there is no overall estimation of the prevalence of human leishmaniasis in Sudan

Research motivation

The lack of evidence about human leishmaniasis in Sudan may prevent health care policymakers and stakeholders from developing and adopting a suitable prevention program.

Research objectives

The objective of this study was to find the pooled prevalence of leishmaniasis and its associated factors among Sudanese citizens.

Research methods

A systematic literature search was conducted before the 4th of August 2021, from Scopus, Web of Science, PubMed, and MEDLINE, African Journals Online (AJOL), ResearchGate, direct Google search, Google Scholar, and universities websites.

Research results

A total of 20 articles were included in this meta-analysis after 220 articles had been subjected to full-text evaluations, and the overall pooled prevalence of human leishmaniasis in Sudan was 21% (with confidence interval 12%-30%).

Research conclusions

Human leishmaniasis infection is still endemic in many regions in Sudan and is highly prevalent in central and eastern Sudan, and cutaneous leishmaniasis is the most prevalent in the country.

Research perspectives

More studies need to be done in Sudan to cover all epidemiological aspects of the disease in humans and animals under the umbrella of one health approach, with special emphasis on the health and economic impacts of the disease.
  34 in total

1.  Preliminary entomological observations in a highland area of Amhara region, northern Ethiopia, with epidemic visceral leishmaniasis.

Authors:  T Gebre-Michael; M Balkew; T Alamirew; N Gudeta; M Reta
Journal:  Ann Trop Med Parasitol       Date:  2007-06

Review 2.  Leishmaniasis in the Sudan: a literature review with emphasis on clinical aspects.

Authors:  O F Osman; P A Kager; L Oskam
Journal:  Trop Med Int Health       Date:  2000-08       Impact factor: 2.622

3.  Cutaneous leishmaniasis in Hormozgan, Iran.

Authors:  S Zare; S Baghestani
Journal:  Int J Dermatol       Date:  2001-10       Impact factor: 2.736

4.  Studies on the leishmaniases in the Sudan. 1. Epidemic of cutaneous leishmaniasis in Khartoum.

Authors:  S H el-Safi; W Peters
Journal:  Trans R Soc Trop Med Hyg       Date:  1991 Jan-Feb       Impact factor: 2.184

Review 5.  Cutaneous leishmaniasis in Iran: A systematic review and meta-analysis.

Authors:  Sadaf Sabzevari; Saeed Hosseini Teshnizi; Azar Shokri; Fariborz Bahrami; Fatemeh Kouhestani
Journal:  Microb Pathog       Date:  2021-02-01       Impact factor: 3.738

6.  Impact of Environmental and Climate Factors on Spatial Distribution of Cutaneous Leishmaniasis in Northeastern Iran: Utilizing Remote Sensing.

Authors:  Mohammad Reza Shirzadi; Mohammad Javanbakht; Hassan Vatandoost; Nahid Jesri; Abedin Saghafipour; Reza Fouladi-Fard; Alireza Omidi-Oskouei
Journal:  J Arthropod Borne Dis       Date:  2020-03-31       Impact factor: 1.198

Review 7.  Visceral Leishmaniasis and HIV coinfection in East Africa.

Authors:  Ermias Diro; Lutgarde Lynen; Koert Ritmeijer; Marleen Boelaert; Asrat Hailu; Johan van Griensven
Journal:  PLoS Negl Trop Dis       Date:  2014-06-26

Review 8.  A review of visceral leishmaniasis during the conflict in South Sudan and the consequences for East African countries.

Authors:  Waleed Al-Salem; Jennifer R Herricks; Peter J Hotez
Journal:  Parasit Vectors       Date:  2016-08-22       Impact factor: 3.876

9.  Leishmaniasis in Ethiopia: A systematic review and meta-analysis of prevalence in animals and humans.

Authors:  Ayalew Assefa
Journal:  Heliyon       Date:  2018-08-07

Review 10.  Prevalence and Risk Factors of Human Leishmaniasis in Ethiopia: A Systematic Review and Meta-Analysis.

Authors:  Mekonnen Haftom; Pammla Petrucka; Kbrom Gemechu; Jemila Nesro; Embay Amare; Tsegu Hailu; Yohannes Ashebir; Gdiom Gebreheat; Haftea Hagos; Destaalem Gebremedhin; Alem Gebremariam
Journal:  Infect Dis Ther       Date:  2020-11-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.